April 11
Leap Therapeutics announced it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12.66M shares of its common stock at a price of $2.82 per share and pre-funded warrants to purchase 1.52M shares of common stock at a price of $2.819 per share of common stock issuable upon exercise of the pre-funded warrants, in a private placement. Leap anticipates the gross proceeds from the private placement will be approximately $40M, before deducting any offering-related expenses. The financing is expected to close on April 15, subject to satisfaction of customary closing conditions. The private placement investors included new and existing investors, including Gilead Sciences, Samsara BioCapital, 683 Capital Partners, LP, Laurion Capital Management, and Rock Springs Capital. J.P. Morgan acted as the exclusive placement agent for the transaction.